Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Avutometinib and defactinib + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin |
| Synonyms | Avutometinib and Defactinib + mFOLFORINOX |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Avutometinib and defactinib | Avmapki Fakzynja Co-pack | FAK inhibitor 16 MEK inhibitor (Pan) 27 MEK1 Inhibitor 28 MEK2 Inhibitor 26 RAF Inhibitor (Pan) 29 | Avmapki Fakzynja Co-pack (avutometinib and defactinib) is a combination drug that consists of the RAF/MEK inhibitor Avutometinib and the FAK inhibitor Defactinib, which may synergistically inhibit tumor growth (PMID: 39240189). Avmapki Fakzynja Co-pack (avutometinib and defactinib) is FDA-approved for use in patients with KRAS-mutant recurrent low-grade serous ovarian cancer (FDA.gov). | |
| Fluorouracil | Adrucil | 5-FU|5-Fluorouracil | Chemotherapy - Antimetabolite 14 | Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent that interferes with DNA and RNA synthesis, thereby preventing cancer cell growth (PMID: 28520376). Adrucil (fluorouracil) is FDA-approved for use in patients with adenocarcinoma of the colon, rectum, breast, stomach, and pancreas (FDA.gov). |
| Irinotecan | Camptosar | CPT-11 | TOPO1 inhibitor 11 | Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov). |
| Leucovorin | Wellcovorin | Calcium folinate|Calcium citrovorum factor|folinic acid | Chemotherapy - Antimetabolite 14 | Wellcovorin (leucovorin) is a metabolite of folate that enhances the efficacy of fluoruracil (PMID: 32490554). |
| Oxaliplatin | Eloxatin | Diaminocyclohexane Oxalatoplatinum | Chemotherapy - Platinum 7 | Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity, and is FDA approved for colorectal cancer (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07824960 | Phase Ib/II | Avutometinib and defactinib + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma (Panc 004) | Not yet recruiting | USA | 0 |